Vol 26, No 3 (2021)
Case report
Published online: 2021-04-08
A clinical case of diagnosis of breast cancer in patients with family history of BRCA mutations 1
Rep Pract Oncol Radiother 2021;26(3):463-469.
Abstract
BACKGROUND: The incidence of breast cancer is growing rapidly worldwide (1.7 million new cases and 600,000 deaths per year). Moreover, about 10% of breast cancer cases occur in young women under the age of 45. The aim of the study was to report a rare case of BRCA1-mutated breast cancer in a young patient with multiple affected relatives.
CASE PRESENTATION: Breast cancer is due to a genetic predisposition with BRCA1 and BRCA2 representing a significant proportion of families with a very high risk of developing the disease over a lifetime of up to 50–80%.
In this paper we report a case of a 29-year-old woman with a confirmed diagnosis of left breast carcinoma.
CONCLUSIONS: Mutations of the BRCA1 gene were revealed in the patient, in two of her sisters, brother and brother’s daughter.
Keywords: BRCA mutationbreast cancercase reportheredity
References
- Martin AM, Blackwood MA, Antin-Ozerkis D, et al. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic. J Clin Oncol. 2001; 19(8): 2247–2253.
- Slattery ML, Kerber RA. A comprehensive evaluation of family history and breast cancer risk. The Utah Population Database. JAMA. 1993; 270(13): 1563–1568.
- Peto J, Collins N, Barfoot R, et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst. 1999; 91(11): 943–949.
- Chen S, Iversen ES, Friebel T, et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol. 2006; 24(6): 863–871.
- Rich TA, Woodson AH, Litton J, et al. Hereditary breast cancer syndromes and genetic testing. J Surg Oncol. 2015; 111(1): 66–80.
- Chen S, Parmigiani G. Meta‐analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007;25:1329-33. J Clin Oncol. 2007; 25(11): 1329–1333.
- Hartman AR, Kaldate RR, Sailer LM, et al. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer. 2012; 118(11): 2787–2795.
- Kwon JS, Gutierrez-Barrera AM, Young D, et al. Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol. 2010; 28(27): 4214–4220.
- Gonzalez-Angulo AM, Timms KM, Liu S, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011; 17(5): 1082–1089.
- Martin AM, Blackwood MA, Antin-Ozerkis D, et al. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic. J Clin Oncol. 2001; 19(8): 2247–2253.
- Couch FJ, Weber BL. Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. Breast Cancer Information Core. Hum Mutat. 1996; 8(1): 8–18.
- Moynahan ME, Pierce AJ, Jasin M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell. 2001; 7(2): 263–272.
- Welcsh PL, Owens KN, King MC. Insights into the functions of BRCA1 and BRCA2. Trends Genet. 2000; 16(2): 69–74.
- Patel KJ, Yu VP, Lee H, et al. Involvement of Brca2 in DNA repair. Mol Cell. 1998; 1(3): 347–357.
- Gowen LC, Avrutskaya AV, Latour AM, et al. BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science. 1998; 281(5379): 1009–1012.
- Byrski T, Gronwald J, Huzarski T, et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol. 2010; 28(3): 375–379.
- Livraghi L, Garber JE. PARP inhibitors in the management of breast cancer: current data and future prospects. BMC Med. 2015; 13: 188.
- Delaloge S, Wolp-Diniz R, Byrski T, et al. Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study. Ann Oncol. 2014; 25(6): 1152–1158.
- Balmaña J, Cruz C, Garber J, et al. Lurbinectedin (PM01183) activity in BRCA1/2‐associated or unselected metastatic breast cancer. Interim results of an ongoing phase II trial. Cancer Re. 2015; 75 (Suppl 9): P3‐13‐01.
- Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418): 61–70.
- Garber JE, Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol. 2005; 23(2): 276–292.
- Wang Q. Cancer predisposition genes: molecular mechanisms and clinical impact on personalized cancer care: examples of Lynch and HBOC syndromes. Acta Pharmacol Sin. 2016; 37(2): 143–149.
- Pathak A, Rathore A, Ranjan S, et al. BRCA 1 and 2 mutations in carcinoma breast: An Indian study. Clin Cancer Invest J. 2018; 7(3): 97.
- Daly MB, Pilarski R, Berry M, et al. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017. J Natl Compr Canc Netw. 2017; 15(1): 9–20.
- Sapkota Y. Germline DNA variations in breast cancer predisposition and prognosis: a systematic review of the literature. Cytogenet Genome Res. 2014; 144(2): 77–91.
- Skol AD, Sasaki MM, Onel K. The genetics of breast cancer risk in the post-genome era: thoughts on study design to move past BRCA and towards clinical relevance. Breast Cancer Res. 2016; 18(1): 99.
- Nik-Zainal S, Davies H, Staaf J, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016; 534(7605): 47–54.
- Janavičius R. Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control. EPMA J. 2010; 1(3): 397–412.
- Apsalikov B, Manambaeva Z, Ospanov E. BRCA1 and ТР53 Gene-Mutations: Family Predisposition and Radioecological Risk of Developing Breast Cancer. Asian Pac J Cancer P. 2016; 17(8): 4059–4062.
- Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015; 33(3): 244–250.
- Kotsopoulos J. Mutations and Breast Cancer Prevention. Cancers (Basel). 2018; 10(12).
- National Cancer Institute at the National Institute of Health. The Cancer Genome Atlas Program; 2020. https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga (17 October 2020).
- Zhang H, Liu G, Dziubinski M, et al. Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells. Breast Cancer Res Treat. 2008; 112(2): 217–227.
- Shangary S, Wang S. Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res. 2008; 14(17): 5318–5324.
- National Comprehensive Cancer Network. NCCN Guidelines® & Clinical Resources. Genetic Familial High-Risk Assessment: Breast and Ovarian. Version 2.